Gemsenjäger E, Heitz P, Martina B
Chirurgische Klinik, Spital Neumünster, Zollikerberg/Zürich.
Schweiz Med Wochenschr. 1995 Nov 18;125(46):2226-36.
Controversy still exists regarding the appropriate treatment for differentiated thyroid carcinoma, i.e. the extent of surgery and the usefulness of prophylactic 131I thyroid ablation. However, the debate is nowadays confined to those patients who may be categorized as having a favorable prognosis with respect to tumor-related death or serious recurrence, and the point of discussion is essentially the optimal treatment to prevent curable recurrences. From the literature it may be deduced that patients with a node negative papillary tumor of stage I and II in the age-related TNM classification system, and patients with a minimally invasive follicular carcinoma, have an excellent prognosis with respect to survival and recurrence. In a prospective study during a 20-year period from one surgical and one pathological institution 136 consecutive patients were treated. Patients with an incidental pT1 N0 tumor, or with a stage I or II node negative papillary carcinoma, or with a minimally invasive follicular carcinoma respectively, had a reduced extent of treatment. This consisted in resection for the concomitant benign goiter (7%), hemithyroidectomy (32%), or total thyroidectomy without 131I ablation (18%). All other patients, including those with a node positive tumor in stage I or II, had total thyroidectomy and 131I ablation (43%). Patients with a multifocal tumor had total thyroidectomy with or without 131I ablation. Hemi- or total thyroidectomy was technically carried out by capsular dissection with identification of the parathyroids, as introduced by Kocher and Halsted. Peritracheal and -laryngeal nodes were regularly searched for, and functional neck dissection was done in node positive tumors. Total thyroidectomy was carried out by completion thyroidectomy in 29 (35%) of the 83 patients. 5 patients (7%) with papillary carcinoma, all in stage III or IV, and 5 patients (8%) with follicular carcinoma, all with a high degree of capsular angio-invasion, died from the tumor 6 months to 16 years after diagnosis. A further patient with a high degree follicular carcinoma is alive with residual disease. All these patients with an unfavorable course underwent total thyroidectomy and 131I ablation as initial therapy. Two patients with papillary carcinoma had a presumptively curable recurrence, namely, a node recurrence in a pT1 N1 tumor (following total thyroidectomy and radio-iodine ablation), and a contralateral recurrence after hemithyroidectomy in a pT2 N0 tumor in a young patient. In sum, in no case with an unfavorable course was a radical therapy omitted initially, and less than total thyroidectomy with 131I ablation (n = 77 [57%]) led to a (curable) recurrence in only one instance (1.3%).(ABSTRACT TRUNCATED AT 400 WORDS)
关于分化型甲状腺癌的恰当治疗,即手术范围以及预防性¹³¹I甲状腺消融的效用,目前仍存在争议。然而,如今这场争论仅限于那些在肿瘤相关死亡或严重复发方面可能被归类为预后良好的患者,讨论的焦点本质上是预防可治愈性复发的最佳治疗方法。从文献中可以推断,在年龄相关的TNM分类系统中处于I期和II期且淋巴结阴性的乳头状肿瘤患者,以及微小浸润性滤泡癌患者,在生存和复发方面预后极佳。在一项来自一家外科和一家病理机构的为期20年的前瞻性研究中,连续治疗了136例患者。分别患有偶然发现的pT1 N0肿瘤、I期或II期淋巴结阴性乳头状癌或微小浸润性滤泡癌的患者,治疗范围有所缩小。这包括切除合并的良性甲状腺肿(7%)、甲状腺次全切除术(32%)或不进行¹³¹I消融的甲状腺全切除术(18%)。所有其他患者,包括I期或II期淋巴结阳性肿瘤患者,均接受甲状腺全切除术和¹³¹I消融(43%)。多灶性肿瘤患者接受有或无¹³¹I消融的甲状腺全切除术。甲状腺次全切除术或全切除术在技术上是通过包膜剥离并识别甲状旁腺来进行的,这是由科赫尔和霍尔斯特德引入的方法。常规探查气管旁和喉旁淋巴结,对淋巴结阳性肿瘤进行功能性颈清扫术。83例患者中有29例(35%)通过完成甲状腺切除术进行甲状腺全切除术。5例(7%)乳头状癌患者,均处于III期或IV期,以及5例(8%)滤泡癌患者,均有高度的包膜血管浸润,在诊断后6个月至16年死于肿瘤。另有1例高度滤泡癌患者仍有残留疾病存活。所有这些病程不佳的患者均接受甲状腺全切除术和¹³¹I消融作为初始治疗。2例乳头状癌患者有推测可治愈的复发,即1例pT1 N1肿瘤(甲状腺全切除术后及放射性碘消融后)出现淋巴结复发,以及1例年轻患者pT2 N0肿瘤甲状腺次全切除术后出现对侧复发。总之,在任何病程不佳的病例中,最初均未省略根治性治疗,而少于甲状腺全切除术加¹³¹I消融(n = 77 [57%])仅在1例(1.3%)中导致(可治愈的)复发。(摘要截取自400字)